Medpace Holdings, Inc. $MEDP Stake Cut by Pitcairn Co.

Pitcairn Co. cut its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 60.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 850 shares of the company’s stock after selling 1,282 shares during the quarter. Pitcairn Co.’s holdings in Medpace were worth $437,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Clarkston Capital Partners LLC acquired a new position in Medpace in the second quarter valued at approximately $40,569,000. Cibc World Market Inc. acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $5,033,000. Brighton Jones LLC raised its position in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after purchasing an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after purchasing an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 0.3%

NASDAQ:MEDP opened at $470.59 on Monday. The business’s 50-day moving average price is $533.94 and its 200 day moving average price is $539.47. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The firm has a market cap of $13.36 billion, a P/E ratio of 30.76, a PEG ratio of 2.26 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same quarter last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Royal Bank Of Canada initiated coverage on Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price objective for the company. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target for the company in a research report on Friday. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.